Ann: Proposed USA Medicare Changes, page-26

Management team which continues to deliver for shareholders. I'm happy to keep buying anything under 30c (yes my max buy price continues to rise as I spend more time examining this unexpectedly very bullish announcement). I'm pleasantly surprised to say that the high growth thesis is still in play here, if anything it will potentially be an even stronger FY for this company as they take significant market share from competitors. Should be breakeven this year, profitable next, making it the perfect investment for the current macro environment

Wouldn't it be great timing if the company can secure a deal for 2RT whilst touring the USA this month. That, in addition to what is likely to be a very bullish sales update later this month, would really transform this company from being a largely unknown ASX listed stock to market darling status quite fast